ClinicalTrials.gg
CompletedNCT01946789Updated Jan 22, 2025Results posted

A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of ALT-803 in Advanced Solid Tumors, sponsored by Altor BioScience. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-22.

Primary conditionMelanomaRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Melanoma
Why
  1. The study's title name Melanoma, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Altor BioScience (part of ImmunityBio, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,050 studies in Melanoma with a site in United States — 244 open to participants now, 438 under way, 32 of them phase 3. Melanoma · United States.

Enrollment
1,053rd of 1,750
26 · median 37
Started
2014
with 80 others
Phase 1
648 of 2,050
55 open now
Registered
933rd of 2,050
by date

Among the 2,050 studies in Melanoma with a site in United States, this one is the 1,053rd largest by enrollment of the 1,750 interventional ones that give a count, is one of 81 that started in 2014, is one of 648 in phase 1, and was the 933rd registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

244 of the 2,050 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:

239 more — sign in →

All 244 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,050 studies in Melanoma with a site in United States, or all of them as a file.
02

Study summary

The proposed clinical trial is a phase I, open-label, multi-center, dose-escalation study of ALT-803 in patients with surgically incurable advanced solid tumors: melanoma, renal cell, non-small cell lung and squamous cell head and neck cancer

Read the detailed description

This trial will investigate the safety and immunogenicity, immunomodulatory properties, and clinical benefits of treatment with weekly doses of ALT-803 in patients with advanced solid tumors.

03

Conditions studied

  • Advanced Solid Tumors

Browse trials for

Keywords

  • cancer
  • IL-15
  • melanoma
  • metastatic
  • unresectable
  • solid tumors
  • renal cell
  • non-small cell lung
  • squamous cell head and neck
04

In context

Melanoma Reclassified

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

This study's enrollment of 26 is below the median of 40 across 2,652 interventional studies indexed under Melanoma.

Browse Melanoma studies →

Lead sponsor

Altor BioScience is the lead sponsor of 15 studies on the registry; none are open to participants now.

First submitted before Altor BioScience became part of ImmunityBio, Inc..

Compared within Melanoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

ENTRY CRITERIA:

DISEASE CHARACTERISTICS:

  • Histological or cytological confirmed in the following disease groups: melanoma that is or unresectable, non-small cell lung carcinoma, renal cell carcinoma or squamous cell head and neck carcinoma, for which standard curative or palliative measures do not exist or are no longer effective.
  • Primary site may be cutaneous or unknown, but mucosal and ocular primaries are excluded.
  • Patients with non-small lung cancer must have had prior EGFR and ALK testing. Patients with sensitizing mutations in EGFR or ALK rearrangements should have been treated with prior targeted agents and have had progression or discontinued due to toxicity from these agents.
  • No patients with known .

PRIOR/CONCURRENT THERAPY:

  • At least one prior therapy using an agent with the potential for prolonged remission.
  • Patients with BRAF v600 mutation should be excluded or may be included after experiencing progression following treatment with BRAF inhibitor regimen or if they consent to forgo FDA-approved therapies that increase median survival.
  • At least 4 weeks from last dose of prior chemotherapy or immunomodulator therapy with full recovery of acute toxicities. For patients coming off molecularly-targeted therapy, at least 2 weeks since last dose and recovery from laboratory and constitutional toxicities.
  • At least 2 weeks from completion of prior radiation therapy with full recovery from toxicities.
  • At least 4 weeks from last dose of prior therapy with recovery to meet baseline eligibility criteria.
  • Not receiving any current anticancer therapy
  • No patients who have had chemotherapy, targeted therapy, or radiotherapy and have not recovered from acute toxicity to their pretreatment baseline or to a grade 1 level within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study. For resolution of toxicity from prior immune therapy, patients must be off for at least 30 days without relapse of autoimmune toxicity, or it must be at least 30 days from their last dose of infliximab or related therapy without relapse of autoimmune toxicity.
  • No patients who are receiving any other investigational agents.
  • No patients who are receiving chronic systemic or regular inhaled corticosteroid use within 7 days prior to initiation of protocol therapy.
  • No immunosuppressive therapy within 30 days prior to treatment start.

PATIENT CHARACTERISTICS

  • Age >18 years
  • Both men and women of all races and ethnic groups are eligible.

Performance Status

  • performance status ≤1
  • of greater than 6 months.

Bone Marrow Function

  • leukocytes ≥3,000/mcL
  • absolute lymphocyte count ≥500/mcL
  • ≥1,000/mcL (without hematopoietic growth factors)
  • ≥100,000/mcL (without transfusion)
  • ≥ 10 gm/dL (may be transfused but must be stable without clinical evidence of ongoing blood loss or hemolysis)

Hepatic Function

  • total within normal institutional limits
  • (SGOT)/ALT(SGPT) ≤2.5 × institutional

Kidney Function

  • Creatinine within normal institutional limits OR
  • ≥60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.

Pulmonary Function

  • No history of severe or emphysema or interstitial lung disease currently on home supplemental oxygen. Patients with NSCLC with stable COPD or emphysema not requiring supplemental oxygen are eligible.

Cardiac Function

  • No symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia. Patients who have underlying risk factors for cardiac disease should be excluded or undergo clearance stress-based cardiac function testing. The pre-treatment must be \<500 msec.
  • No class II or greater congestive heart failure as described in the Functional Classification criteria or serious arrhythmias likely to increase the risk of cardiac complications of cytokine therapy.

Other

  • Women of and men must agree to use adequate .
  • Ability to understand and the willingness to sign a written document.
  • No uncontrolled inter-current illness or psychiatric illness/social situations that would limit compliance with study requirements.
  • No pregnant women.
  • No -positive patients.
  • No positive serology or active infection.
  • No active bacterial or fungal infection.
  • No inability to home monitor blood pressure.
  • Patients with thyroid disease should be excluded unless euthyroid on suppressive or replacement therapy.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    N-803 IV 0.3/0.5 ug/kg

    Biological: ALT-803

  • Experimental
    N-803 IV 1.0 ug/kg

    Biological: ALT-803

  • Experimental
    N-803 IV 3.0 ug/kg

    Biological: ALT-803

  • Experimental
    N-803 IV 6.0 ug/kg

    Biological: ALT-803

  • Experimental
    N-803 Subcutaneous 6.0 ug/kg

    Biological: ALT-803

  • Experimental
    N-803 Subcutaneous 10.0 ug/kg

    Biological: ALT-803

  • Experimental
    N-803 Subcutaneous 15.0 ug/kg

    Biological: ALT-803

  • Experimental
    N-803 Subcutaneous 20.0 ug/kg

    Biological: ALT-803

  • Experimental
    N-803 Intratumoral 10.0 ug/kg followed by N-803 15.0 ug/kg subcutaneous

    Biological: ALT-803

Interventions

  • BiologicalALT-803

    N-803 will be administered at the following doses intravenously: 0.3/0.5, 1.0, 3.0, 6.0 ug/kg N-803 will be administered at the following does subcutaneously: 6.0, 10.0, 15.0, 20.0 ug/kg N-803 will be administered intratumorally at a dose of 10.0 ug/kg, followed by N-803 administered subcutaneously at a dose of 15.0 ug/kg. Each treatment cycle consists of 4 weeks on therapy and 2 weeks off. Patients will receive weekly dose of ALT-803 for 4 weeks (Days 1, 8, 15, and 22) used for the identification of the OBD and MTD. After a 2-week rest period (Weeks 5 and 6) and recovery of any dose limiting toxicities to grade 0-1 of Cycle 1, a second 6-week cycle (4 weeks on treatment and 2 weeks off) can begin. After a rest period during Weeks 5 and 6 of Cycle 2, stable or benefitting patients assessed at week 8 +/- 1 may receive up to 2 additional 6-week cycles.

07

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity

    The safety endpoint is the MTD of ALT-803, defined as the dose level below that at which ≥2 of 6 patients experience a DLT.

    Time frame: 9 months

Secondary outcomes

  1. Number of Participants Who Developed Anti-drug Antibodies to ALT-803

    Immunogenicity of ALT-803 assessed by ELISA

    Time frame: 14 days post final dose, up to 135 days

  2. To Evaluate the Effect of Escalating Doses of ALT-803: Pharmacokinetics (Half Life and Tmax)

    Pharmacokinetics of ALT-803 assessed by ELISA

    Time frame: 24 hours post dose

  3. To Evaluate the Effect of Escalating Doses of ALT-803: Pharmacokinetics (Cmax)

    Pharmacokinetics of ALT-803 assessed by ELISA

    Time frame: 24 hours after first dose

  4. To Evaluate the Effect of Escalating Doses of ALT-803: Pharmacokinetics (AUC 0-t, AUC0-24, AUC0-infinity)

    Pharmacokinetics of ALT-803 assessed by ELISA

    Time frame: 24 hours after first dose

  5. To Evaluate the Effect of Escalating Doses of ALT-803: Interferon Gamma (IFN-γ)

    The level of immune response to autochthonous viral and tumor antigens by interferon gamma (IFN-γ) ELISPOT

    Time frame: Cycle 1 Week 1, pre-dose; Cycle 1 Week 1, 30 minutes post dose; Cycle 1 Week 1, 2 hours post dose; Cycle 1 Week 1, 4 hours post dose; Cycle 1 Week 1, 8 hours post dose; Cycle 1 Week 1, 24 hours post dose

  6. Objective Response Rate

    Number of patients with CR, PR, SD, and PD

    Time frame: Up to 6 months

08

Results

Posted Jan 22, 2025

Participant flow

Participant flow — Overall Study
MilestoneN-803 IV 0.3/0.5 ug/kgN-803 IV 1.0 ug/kgN-803 IV 3.0 ug/kgN-803 IV 6.0 ug/kgN-803 Subcutaneous 6.0 ug/kgN-803 Subcutaneous 10.0 ug/kgN-803 Subcutaneous 15.0 ug/kgN-803 Subcutaneous 20.0 ug/kgN-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg Subcutaneous
Started233333432
Completed211010020
Not completed022323412
Withdrew: Death021111312
Withdrew: Progressive disease001002000
Withdrew: Withdrawal by subject000210100

Outcome measures

PrimaryDose Limiting Toxicity

The safety endpoint is the MTD of ALT-803, defined as the dose level below that at which ≥2 of 6 patients experience a DLT.

Time frame:
9 months
Reported as:
Count of participants · Participants
Dose Limiting Toxicity
ParticipantsN-803 IV 0.3/0.5 ug/kgN-803 IV 1.0 ug/kgN-803 IV 3.0 ug/kgN-803 IV 6.0 ug/kgN-803 Subcutaneous 6.0 ug/kgN-803 Subcutaneous 10.0 ug/kgN-803 Subcutaneous 15.0 ug/kgN-803 Subcutaneous 20.0 ug/kgN-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg Subcutaneous
Dose Limiting Toxicity000000100
SecondaryNumber of Participants Who Developed Anti-drug Antibodies to ALT-803

Immunogenicity of ALT-803 assessed by ELISA

Time frame:
14 days post final dose, up to 135 days
Reported as:
Count of participants · Participants
Number of Participants Who Developed Anti-drug Antibodies to ALT-803
ParticipantsN-803 IV 0.3/0.5 ug/kgN-803 IV 1.0 ug/kgN-803 IV 3.0 ug/kgN-803 IV 6.0 ug/kgN-803 Subcutaneous 6.0 ug/kgN-803 Subcutaneous 10.0 ug/kgN-803 Subcutaneous 15.0 ug/kgN-803 Subcutaneous 20.0 ug/kgN-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg Subcutaneous
Number of Participants Who Developed Anti-drug Antibodies to ALT-803000000000
SecondaryTo Evaluate the Effect of Escalating Doses of ALT-803: Pharmacokinetics (Half Life and Tmax)

Pharmacokinetics of ALT-803 assessed by ELISA

Time frame:
24 hours post dose
Reported as:
Mean · hours
To Evaluate the Effect of Escalating Doses of ALT-803: Pharmacokinetics (Half Life and Tmax)
hoursN-803 IV 0.3ug/kgN-803 IV 1.0 ug/kgN-803 IV 3.0 ug/kgN-803 IV 6.0 ug/kgN-803 Subcutaneous 6.0 ug/kgN-803 Subcutaneous 10.0 ug/kgN-803 Subcutaneous 15.0 ug/kgN-803 Subcutaneous 20.0 ug/kgN-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg SubcutaneousN-803 IV 0.5ug/kg
Half life2.23 (2.23 to 2.23)4.58 (1.36 to 7.79)2.53 (2.53 to 2.53)1.41 (0.751 to 2.06)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)2.73 (2.3 to 3.15)NA (NA to NA)
Tmax0.583 (0.583 to 0.583)0.542 (0.517 to 0.567)0.667 (0.533 to 0.8)0.650 (0.55 to 0.75)6.06 (4.0 to 8.12)24.0 (23.9 to 24.0)16.1 (8.0 to 24.3)16.1 (8.12 to 24.0)0.508 (0.5 to 0.517)0.500 (0.500 to 0.500)
SecondaryTo Evaluate the Effect of Escalating Doses of ALT-803: Pharmacokinetics (Cmax)

Pharmacokinetics of ALT-803 assessed by ELISA

Time frame:
24 hours after first dose
Reported as:
Mean · ng/mL
To Evaluate the Effect of Escalating Doses of ALT-803: Pharmacokinetics (Cmax)
ng/mLN-803 IV 0.3 ug/kgN-803 IV 1.0 ug/kgN-803 IV 3.0 ug/kgN-803 IV 6.0 ug/kgN-803 Subcutaneous 6.0 ug/kgN-803 Subcutaneous 10.0 ug/kgN-803 Subcutaneous 15.0 ug/kgN-803 Subcutaneous 20.0 ug/kgN-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg SubcutaneousN-803 IV 0.5 ug/kg
To Evaluate the Effect of Escalating Doses of ALT-803: Pharmacokinetics (Cmax)91.2 (91.2 to 91.2)11.5 (10.2 to 12.8)49.8 (39.9 to 59.6)86.0 (79.0 to 93.0)0.276 (0.152 to 0.401)0.352 (0.290 to 0.413)0.685 (0.443 to 0.928)0.280 (0.252 to 0.307)72.6 (26.5 to 119)2.26 (2.26 to 2.26)
SecondaryTo Evaluate the Effect of Escalating Doses of ALT-803: Pharmacokinetics (AUC 0-t, AUC0-24, AUC0-infinity)

Pharmacokinetics of ALT-803 assessed by ELISA

Time frame:
24 hours after first dose
Reported as:
Mean · hr*ng/mL
To Evaluate the Effect of Escalating Doses of ALT-803: Pharmacokinetics (AUC 0-t, AUC0-24, AUC0-infinity)
hr*ng/mLN-803 IV 0.3ug/kgN-803 IV 1.0 ug/kgN-803 IV 3.0 ug/kgN-803 IV 6.0 ug/kgN-803 Subcutaneous 6.0 ug/kgN-803 Subcutaneous 10.0 ug/kgN-803 Subcutaneous 15.0 ug/kgN-803 Subcutaneous 20.0 ug/kgN-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg SubcutaneousN-803 IV 0.5ug/kg
AUC 0-t236 (236 to 236)14.7 (10.5 to 18.8)105 (65.2 to 145)289 (186 to 392)4.66 (2.74 to 6.59)5.19 (4.86 to 5.51)10.9 (8.67 to 13.2)4.57 (3.73 to 5.41)323 (82.1 to 565)NA (NA to NA)
AUC0-24236 (236 to 236)14.7 (10.6 to 18.8)145 (145 to 145)290 (187 to 393)2.73 (2.73 to 2.73)4.86 (4.86 to 4.86)10.9 (8.56 to 13.2)4.56 (3.73 to 5.4)323 (82.1 to 564)NA (NA to NA)
AUC0-infinity236 (236 to 236)15.0 (10.5 to 19.4)145 (145 to 145)290 (187 to 393)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)324 (82.4 to 565)NA (NA to NA)
SecondaryTo Evaluate the Effect of Escalating Doses of ALT-803: Interferon Gamma (IFN-γ)

The level of immune response to autochthonous viral and tumor antigens by interferon gamma (IFN-γ) ELISPOT

Time frame:
Cycle 1 Week 1, pre-dose; Cycle 1 Week 1, 30 minutes post dose; Cycle 1 Week 1, 2 hours post dose; Cycle 1 Week 1, 4 hours post dose; Cycle 1 Week 1, 8 hours post dose; Cycle 1 Week 1, 24 hours post dose
Reported as:
Mean · pg/mL
To Evaluate the Effect of Escalating Doses of ALT-803: Interferon Gamma (IFN-γ)
pg/mLN-803 IV 0.3/0.5 ug/kgN-803 IV 1.0 ug/kgN-803 IV 3.0 ug/kgN-803 IV 6.0 ug/kgN-803 Subcutaneous 6.0 ug/kgN-803 Subcutaneous 10.0 ug/kgN-803 Subcutaneous 15.0 ug/kgN-803 Subcutaneous 20.0 ug/kgN-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg Subcutaneous
C1, W1 pre dose2.7 ± 0.50371.528 ± 2.16092.015 ± 2.84960 ± 00.326 ± 0.38332.741 ± 2.37922.659 ± 4.60594.445 ± 7.69875.955 ± 0.5356
C1, W1 30min post dose0 ± 03.433 ± 4.85511.420 ± 2.00820 ± 00.163 ± 0.28290.692 ± 1.19942.659 ± 4.60591.394 ± 2.41522.397 ± 3.3896
C1, W1 2 hr post dose21.827 ± 25.650622.585 ± 2.994130.605 ± 36.790810.198 ± 13.85270 ± 01.525 ± 1.33730 ± 01.463 ± 2.534243.863 ± 42.2211
C1, W1 4 hr post dose64.947 ± 85.019747.160 ± 37.148557.660 ± 56.497823.295 ± 28.10611.146 ± 1.78921.771 ± 2.23070.607 ± 1.05061.325 ± 2.294378.729 ± 63.0940
C1, W1 8 hr post dose10.022 ± 14.173111.158 ± 4.718615.3 ± 9.89957.597 ± 9.58580 ± 02.123 ± 1.10982.479 ± 4.29391.598 ± 2.767622.293 ± 11.2426
C1, W1 24 hr post dose0 ± 00.728 ± 1.02920.73 ± 1.03240 ± 00.84 ± 0.79623.825 ± 0.52144.389 ± 7.60131.664 ± 2.88234.078 ± 5.7676
SecondaryObjective Response Rate

Number of patients with CR, PR, SD, and PD

Time frame:
Up to 6 months
Reported as:
Count of participants · Participants
Objective Response Rate
ParticipantsN-803 IV 0.3/0.5 ug/kgN-803 IV 1.0 ug/kgN-803 IV 3.0 ug/kgN-803 IV 6.0 ug/kgN-803 Subcutaneous 6.0 ug/kgN-803 Subcutaneous 10.0 ug/kgN-803 Subcutaneous 15.0 ug/kgN-803 Subcutaneous 20.0 ug/kgN-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg Subcutaneous
Stable disease212020301
Progressive disease021303121

Adverse events

Collected over Up to 385 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
N-803 IV 0.3/0.5 ug/kg0/2 (0%)0/2 (0%)2/2 (100%)
N-803 IV 1.0 ug/kg2/3 (66.7%)1/3 (33.3%)3/3 (100%)
N-803 IV 3.0 ug/kg1/3 (33.3%)1/3 (33.3%)3/3 (100%)
N-803 IV 6.0 ug/kg1/3 (33.3%)1/3 (33.3%)3/3 (100%)
N-803 Subcutaneous 6.0 ug/kg1/3 (33.3%)0/3 (0%)3/3 (100%)
N-803 Subcutaneous 10.0 ug/kg1/3 (33.3%)1/3 (33.3%)3/3 (100%)
N-803 Subcutaneous 15.0 ug/kg3/4 (75%)2/4 (50%)4/4 (100%)
N-803 Subcutaneous 20.0 ug/kg1/3 (33.3%)2/3 (66.7%)3/3 (100%)
N-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg Subcutaneous2/2 (100%)0/2 (0%)2/2 (100%)
Most frequent serious events
Most frequent serious events
EventN-803 IV 0.3/0.5 ug/kgN-803 IV 1.0 ug/kgN-803 IV 3.0 ug/kgN-803 IV 6.0 ug/kgN-803 Subcutaneous 6.0 ug/kgN-803 Subcutaneous 10.0 ug/kgN-803 Subcutaneous 15.0 ug/kgN-803 Subcutaneous 20.0 ug/kgN-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg Subcutaneous
Disease progressionGeneral disorders0/20/30/30/30/30/30/41/30/2
Muscular weaknessMusculoskeletal and connective tissue disorders0/20/30/30/30/30/30/41/30/2
Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/21/30/30/30/30/30/40/30/2
HeadacheNervous system disorders0/20/30/30/30/31/30/40/30/2
HaematuriaRenal and urinary disorders0/20/31/30/30/30/30/40/30/2
DyspnoeaRespiratory, thoracic and mediastinal disorders0/20/30/31/30/30/30/40/30/2
AnaemiaBlood and lymphatic system disorders0/20/30/30/30/30/31/40/30/2
Injection site reactionGeneral disorders0/20/30/30/30/30/31/40/30/2
PyrexiaGeneral disorders0/20/30/30/30/30/31/40/30/2
Most frequent other events
Showing 10 of 98
Most frequent other events
EventN-803 IV 0.3/0.5 ug/kgN-803 IV 1.0 ug/kgN-803 IV 3.0 ug/kgN-803 IV 6.0 ug/kgN-803 Subcutaneous 6.0 ug/kgN-803 Subcutaneous 10.0 ug/kgN-803 Subcutaneous 15.0 ug/kgN-803 Subcutaneous 20.0 ug/kgN-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg Subcutaneous
NauseaGastrointestinal disorders2/21/31/31/30/31/30/41/30/2
ChillsGeneral disorders1/22/30/31/30/30/31/41/32/2
FatigueGeneral disorders2/21/32/31/30/33/33/41/32/2
Injection site reactionGeneral disorders0/20/30/30/31/32/34/43/32/2
PyrexiaGeneral disorders1/20/31/31/31/32/31/41/32/2
Lymphocyte count decreasedInvestigations1/20/30/30/30/31/32/41/32/2
Decreased appetiteMetabolism and nutrition disorders0/20/30/30/30/31/31/41/32/2
HypoalbuminaemiaMetabolism and nutrition disorders0/20/30/30/31/31/31/43/31/2
HyponatraemiaMetabolism and nutrition disorders0/20/30/31/30/30/32/40/32/2
PruritusSkin and subcutaneous tissue disorders2/20/30/30/30/30/30/40/30/2

Baseline characteristics

Age, Continuous
Age, Continuous(years)N-803 IV 0.3/0.5 ug/kgN-803 IV 1.0 ug/kgN-803 IV 3.0 ug/kgN-803 IV 6.0 ug/kgN-803 Subcutaneous 6.0 ug/kgN-803 Subcutaneous 10.0 ug/kgN-803 Subcutaneous 15.0 ug/kgN-803 Subcutaneous 20.0 ug/kgN-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg SubcutaneousTotal
Mean38.0 ± 15.5664.7 ± 6.8158.7 ± 10.2669.7 ± 8.0259.3 ± 5.1359.0 ± 3.4663.3 ± 9.8855.3 ± 10.9764.0 ± 19.859.9 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)N-803 IV 0.3/0.5 ug/kgN-803 IV 1.0 ug/kgN-803 IV 3.0 ug/kgN-803 IV 6.0 ug/kgN-803 Subcutaneous 6.0 ug/kgN-803 Subcutaneous 10.0 ug/kgN-803 Subcutaneous 15.0 ug/kgN-803 Subcutaneous 20.0 ug/kgN-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg SubcutaneousTotal
Female20211131011
Male03122212215
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)N-803 IV 0.3/0.5 ug/kgN-803 IV 1.0 ug/kgN-803 IV 3.0 ug/kgN-803 IV 6.0 ug/kgN-803 Subcutaneous 6.0 ug/kgN-803 Subcutaneous 10.0 ug/kgN-803 Subcutaneous 15.0 ug/kgN-803 Subcutaneous 20.0 ug/kgN-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg SubcutaneousTotal
Hispanic or Latino0001010002
Not Hispanic or Latino23323243224
Unknown or Not Reported0000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)N-803 IV 0.3/0.5 ug/kgN-803 IV 1.0 ug/kgN-803 IV 3.0 ug/kgN-803 IV 6.0 ug/kgN-803 Subcutaneous 6.0 ug/kgN-803 Subcutaneous 10.0 ug/kgN-803 Subcutaneous 15.0 ug/kgN-803 Subcutaneous 20.0 ug/kgN-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg SubcutaneousTotal
American Indian or Alaska Native0000000000
Asian0100000001
Native Hawaiian or Other Pacific Islander0000000000
Black or African American0000000000
White22333233223
More than one race0000000000
Unknown or Not Reported0000011002
Advanced Solid Tumors
Advanced Solid Tumors(Participants)N-803 IV 0.3/0.5 ug/kgN-803 IV 1.0 ug/kgN-803 IV 3.0 ug/kgN-803 IV 6.0 ug/kgN-803 Subcutaneous 6.0 ug/kgN-803 Subcutaneous 10.0 ug/kgN-803 Subcutaneous 15.0 ug/kgN-803 Subcutaneous 20.0 ug/kgN-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg SubcutaneousTotal
Count of participants23333343226
09

Study locations

5 sites
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08901, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • University of Washington, Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
10

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in Aug 2017, 39 months.

Results were first posted in Jan 2025, 7 years 5 months after primary completion.

Of 226 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's 39 months is below that.

Counting every sponsor, half of 412 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2013
First posted
Sep 20, 2013
StartActual
May 2014
Primary completionActual
Aug 2017
CompletionActual
Dec 2017
Results first posted
Jan 22, 2025
Last update
Jan 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01946789
Lead sponsor
Altor BioScience
Responsible party
Sponsor
First posted
Sep 20, 2013
Start date
May 2014
Primary completion
Aug 2017
Completion
Dec 2017
Results posted
Jan 22, 2025
Last update
Jan 22, 2025

Study contacts

Marc Ernstoff, MD
principal investigator · Roswell Park Cancer Institute

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nogapendekin alfa inbakicept

Start the discussion